UNSPSC 51351911: Ulipristal

This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J5J15Q2X8. European Medicines Agency schedules Ulipristal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30471. Ulipristal generally arises in the molecular formula C28H35NO3. The term ULIPRISTAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 3, 2007, list 58.) As of Q4 2014, ULIPRISTAL remains the US FDA Preferred Term for this commodity.

Ulipristal bears US NLM identifiers UMLS ID C0300205 and NCI Concept Code C91056. SMILES: CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O.

UNSPSC 51351911 Ulipristal, a Commodity code, addresses the procurement of ulipristal acetate, a selective progesterone receptor modulator used primarily as an emergency contraceptive. State and local governments acquire this pharmaceutical through health departments, public health clinics, school-based health centers, and reproductive health programs that serve uninsured or underinsured populations. The product is typically procured as part of broader emergency contraception formularies or through standing purchase agreements with pharmaceutical distributors or state pharmaceutical benefit managers.

The source provides no recent state and local contract opportunities tagged to this code. Without posted RFPs, RFQs, IBFs, or ITBs in the available data, no issuing bodies, geographic concentration, or representative solicitations can be characterized. This absence of recent activity may reflect the narrow, specialized scope of the commodity — ulipristal is a single-molecule pharmaceutical with limited procurement volume outside large state health systems — or routing of such acquisitions through existing vendor relationships or cooperative purchasing agreements rather than formal competitive solicitations.